DHEA

Intracrine Conversion to Androgens and Estrogens#

DHEA is a weak androgen on its own — the clinically relevant action happens downstream, inside target tissues. Peripheral cells (adipose, skin, prostate, brain, gonads, muscle) express the enzymatic machinery — 3β-HSD, 17β-HSD, 5α-reductase, and aromatase — to convert DHEA locally into androstenedione, testosterone, DHT, estrone, and estradiol. This is the intracrinology model: each tissue sets its own steroid concentration from a circulating DHEA/DHEA-S pool, without needing to move the systemic hormone needle.

"DHEA is transformed in peripheral tissues into active androgens and estrogens via the intracrinology pathway, allowing local control of steroid concentrations and effects." — Labrie F. et al., Frontiers in Neuroendocrinology, 2001

Practically, this is why DHEA behaves differently in different users. A lean 30-year-old with plenty of endogenous testosterone converts it mostly to estradiol (saturating the T step) and feels puffy and soft. A 55-year-old with low adrenal output gets a meaningful androgen and estrogen lift from the same 25 mg. A woman gets a disproportionately strong androgenic response at a fraction of the male dose. The compound is a substrate — what it becomes depends on your enzymes.

Dose-Dependent Hormonal Shift#

At sub-50 mg doses, DHEA mostly restores sub-range DHEA-S and modestly lifts downstream steroids. Above 50 mg/day, testosterone and estradiol climb in a clearly dose-responsive way — and the response is markedly stronger in women than in men.

"DHEA supplementation raised testosterone levels in a dose-dependent manner, notably stronger in women, with clear dose-dependence above 50 mg/day." — Li Y. et al., Journal of Steroid Biochemistry and Molecular Biology, 2020

This is the mechanistic reason 150 mg/day failed to add lean mass over training alone in young, high-T men — the T step saturates and the excess shunts to estradiol rather than productive androgen signaling.

"DHEA (150 mg/d) supplementation did not significantly increase total or free testosterone concentrations or enhance hypertrophic response beyond training alone in young men." — Brown G.A. et al., Journal of Applied Physiology, 1999

The takeaway for physique-focused users: DHEA is a replacement / repletion tool, not a prohormone. Pushing the dose does not overpower a healthy HPG axis; it just feeds aromatase.

The DHEA-S Reservoir and Effective Half-Life#

Oral DHEA is extensively sulfated on first pass to DHEA-S, which acts as a slow-release circulating depot. Desulfation in peripheral tissues regenerates free DHEA on demand, which is why the parent's ~4.5 h plasma half-life is misleading in practice.

"After oral DHEA administration, DHEA-S levels peaked at 4 hours and apparent terminal half-life was prolonged to over 20 hours due to conversion to DHEA-S and slow re-release." — Legrain S. et al., Journal of Clinical Endocrinology & Metabolism, 2000

Two practical consequences:

1. Once-daily dosing is sufficient — splitting doses offers no PK advantage.
2. DHEA-S is the lab marker to track, not free DHEA. DHEA-S integrates exposure and is stable across the day; free DHEA is pulsatile and diurnal and will mislead you.

Neurosteroid Activity (GABA-A, NMDA, Sigma-1)#

Independent of its prohormone role, DHEA and DHEA-S act directly on the CNS. They are non-competitive GABA-A antagonists, positive NMDA modulators, and sigma-1 receptor agonists. This explains the mood, libido, and sleep-depth effects reported by users whose androgen labs barely budged — the neurosteroid effects do not require downstream steroid conversion and can be felt at low doses. The GABA-A antagonism is also why some users find morning dosing alerting and others find evening dosing sleep-enhancing (via sigma-1 and 7α-hydroxy-DHEA metabolites) — individual response varies enough that it's worth testing both windows.

Glucocorticoid Antagonism and the Cortisol Angle#

DHEA opposes glucocorticoid signaling at the tissue level, and the cortisol:DHEA-S ratio is a recognized marker of catabolic load and age-related adrenal drift. For lifters running heavy volume, chronic stress, or aggressive cuts, a depleted DHEA-S pool means cortisol is operating unopposed in peripheral tissues — plausibly contributing to poor recovery, soft-tissue wear, and visceral fat accumulation. Repletion to mid-range DHEA-S is the mechanistic rationale for DHEA's modest but real effects on bone density, skin hydration, and libido in older adults.

"In the DHEAge trial, daily 50 mg DHEA in older adults improved bone mineral density, skin hydration, and libido without serious adverse effects." — Baulieu E.E. et al., PNAS, 2000

This is where DHEA earns its place in the longevity / age-management stack: not as a growth driver, but as an adrenal repletion tool that restores the cortisol-opposing side of the HPA ledger and provides substrate for tissue-level steroid autoregulation. Run it on labs, dose it conservatively, and it does quiet but useful work.

Common (most users)#

• Oily skin and acne — the most frequent complaint, driven by downstream DHT conversion. Back off to 10–25 mg, take with food, and reinforce skincare (salicylic / adapalene). Usually settles within 2–3 weeks once the dose stabilizes.
• Scalp shedding — 5α-reductase-active individuals will notice it first. If you're already on a hair stack (finasteride / dutasteride, topical minoxidil, RU58841), the issue is usually manageable. If not and shedding persists past 4–6 weeks, drop the dose or add 5-AR coverage.
• Estrogenic symptoms on TRT (puffy face, nipple sensitivity, mood lability, soft erections) — DHEA preferentially shunts to estradiol once exogenous T saturates the conversion step. Pull sensitive E2 labs; a small AI dose (anastrozole 0.25 mg twice weekly or less) usually resolves it. If E2 keeps climbing, DHEA isn't for you on cycle.
• Sleep disruption on morning dosing / grogginess on evening dosing — individual response varies via GABA-A / sigma-1 modulation. Try the opposite window for a week before abandoning the compound.
• Mild androgenic effects in women (oily skin, acne, scalp shedding) at doses ≥25 mg — start at 10 mg and titrate on labs, not feel.

Uncommon (dose-dependent or individual)#

• Palpitations / elevated resting heart rate — typically at 100 mg+ in the prohormone-style dose range. Pull the dose back to 25–50 mg; recheck BP and resting HR.
• Mild BP elevation — if you're already running AAS or have borderline hypertension, stack this on top at your own risk. Get cuff readings weekly for the first month.
• Modest HDL reduction — seen in some cohorts at 50–100 mg sustained. Check a lipid panel at 12 weeks; if HDL drops more than ~10 points, reduce the dose.
• Clitoral sensitivity changes / hirsutism in women — dose-dependent, usually at ≥25 mg sustained. Reversible if caught early; back off to 10 mg or discontinue.
• Gynecomastia risk in men with high aromatase activity (higher-BF, older) — manage with dose reduction and a low-dose AI. If tissue is already forming, stop DHEA and address E2 directly.

"DHEA supplementation raised testosterone levels in a dose-dependent manner, notably stronger in women, with clear dose-dependence above 50 mg/day." — Li et al., J Steroid Biochem Mol Biol, 2020

Rare but serious#

• PSA elevation in men 40+ — DHEA feeds androgen and estrogen conversion in prostate tissue. Pull PSA at baseline and annually. Any rise above age-adjusted reference warrants stopping the compound and a urology workup, not dose adjustment.
• Acceleration of an undiagnosed hormone-sensitive tumor — the concern that underlies the cancer contraindications. If you haven't had baseline PSA (men) or a breast exam/mammogram as appropriate (women), do that before starting.
• Hepatic enzyme elevation — rare and generally not clinically significant, but worth a routine LFT panel if you're stacking with orals.

Hard contraindications#

• Hormone-sensitive cancer — active, treated, or family history of concern (prostate, breast, ovarian, uterine). DHEA supplies substrate for both androgen and estrogen pathways via intracrine conversion and has no place in this population.
• Elevated PSA under workup — resolve the PSA question before touching DHEA.
• Pregnancy or possible pregnancy — teratogenic risk from androgen exposure to a female fetus. Not negotiable.
• Lactation.
• Concurrent aromatase inhibitor therapy for breast cancer — DHEA overrides the AI by flooding the system with aromatizable substrate.
• Untreated dyslipidemia or uncontrolled hypertension — baseline and manage first.
• In-competition WADA-tested athletes — DHEA is prohibited at all times, in and out of competition. Non-negotiable if you're drug-tested.

Sex-specific and cycle considerations#

Women are substantially more sensitive than men — 10 mg is a real starting dose, 25 mg is already intermediate, and 50 mg reliably produces androgenic side effects (acne, oily skin, shedding, clitoral changes, voice changes at sustained exposure). Titrate on DHEA-S labs and visible effects, not on "what the bottle says."

Men on TRT should assume DHEA will push estradiol more than testosterone — the T conversion step is already saturated by exogenous dosing. Run it only if DHEA-S labs are genuinely sub-range, start at 10 mg, and pull sensitive E2 at 4–6 weeks.

PCT: DHEA is not a PCT compound. It will not restart LH/FSH and should never replace enclomiphene, clomiphene, or hCG in a recovery protocol. Running it through a bridge for mood and libido support is defensible; running it instead of a SERM is not.